• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $VIR

    Vir Biotechnology Inc.

    Subscribe to $VIR
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: vir.bio

    Peers

    $SANA

    Recent Analyst Ratings for Vir Biotechnology Inc.

    DatePrice TargetRatingAnalyst
    1/29/2024$23.00 → $9.00Overweight → Neutral
    JP Morgan
    9/8/2023$23.00 → $14.00Buy → Neutral
    BofA Securities
    3/6/2023$35.00 → $34.00Neutral → Overweight
    JP Morgan
    2/21/2023$41.00 → $53.00Neutral → Buy
    Goldman
    1/27/2023$18.00 → $30.00Underweight → Equal-Weight
    Morgan Stanley
    9/14/2022$40.00Outperform
    SVB Leerink
    9/9/2022$15.00Underweight
    Morgan Stanley
    3/3/2022$36.00 → $28.00Underperform → Neutral
    Baird
    3/3/2022$36.00 → $28.00Underperform → Neutral
    Robert W. Baird
    12/21/2021$36.00Neutral → Underperform
    Robert W. Baird
    See more ratings

    Vir Biotechnology Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vir Biotechnology downgraded by JP Morgan with a new price target

      JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously

      1/29/24 7:27:38 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology downgraded by BofA Securities with a new price target

      BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously

      9/8/23 7:28:27 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology upgraded by JP Morgan with a new price target

      JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously

      3/6/23 7:36:08 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology upgraded by Goldman with a new price target

      Goldman upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $53.00 from $41.00 previously

      2/21/23 6:26:37 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Vir Biotechnology from Underweight to Equal-Weight and set a new price target of $30.00 from $18.00 previously

      1/27/23 7:25:55 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink initiated coverage on Vir Biotechnology with a new price target

      SVB Leerink initiated coverage of Vir Biotechnology with a rating of Outperform and set a new price target of $40.00

      9/14/22 7:48:51 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Vir Biotechnology with a new price target

      Morgan Stanley initiated coverage of Vir Biotechnology with a rating of Underweight and set a new price target of $15.00

      9/9/22 7:37:23 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology upgraded by Baird with a new price target

      Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously

      3/3/22 8:05:10 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously

      3/3/22 7:15:55 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Vir Biotechnology from Neutral to Underperform and set a new price target of $36.00

      12/21/21 7:32:47 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care